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Abstract
Most genome-wide association studies have explored relationships between genetic variants and
plasma phospholipid fatty acid proportions, but few have examined apparent genetic influences
on the membrane fatty acid profile of red blood cells (RBC). Using RBC fatty acid data from the
Framingham Offspring Study, we analyzed over 2.5 million single nucleotide polymorphisms
(SNPs) for association with 14 RBC fatty acids identifying 191 different SNPs associated with at
least 1 fatty acid. Significant associations (p<1x10-8) were located within five distinct 1 MB
regions. Of particular interest were novel associations between (1) arachidonic acid and
PCOLCE2 (regulates apoA-I maturation and modulates apoA-I levels), and (2) oleic and linoleic
acid and LPCAT3 (mediates the transfer of fatty acids between glycerol-lipids). We also
replicated previously identified strong associations between SNPs in the FADS (chromosome 11)
and ELOVL (chromosome 6) regions. Multiple SNPs explained 8-14% of the variation in 3 high
abundance (>11%) fatty acids, but only 1-3% in 4 low abundance (<3%) fatty acids, with the
notable exception of dihomo-gamma linolenic acid with 53% of variance explained by SNPs.
Further studies are needed to determine the extent to which variations in these genes influence
tissue fatty acid content and pathways modulated by fatty acids.
Key words (up to 6):
PUFA; apoA-I maturation; oleic acid; linoleic acid; arachidonic acid; glycerol-lipids
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1. Introduction
Red blood cell (RBC) proportions of omega-3 and omega-6 fatty acids have well established
relationships with a variety of disease phenotypes and risk factors, including total mortality [1],
acute coronary syndrome [2,3], serum lipid levels [4], inflammatory markers [5], cognitive
function [6] and brain size [7,8] among others. Variation in RBC omega-3 fatty acid levels (i.e.,
proportions, expressed as a percent of total fatty acids) have been shown to possess a strong
heritable component [4,9], suggesting that not only dietary but also genetic factors likely play an
important role in explaining differences between individuals [10,11].
Recently genome-wide association studies (GWAS) have sought to identify common single
nucleotide polymorphisms (SNPs) with fatty acid levels. Initial investigations have focused on
establishing potential relationships between plasma phospholipid fatty acid proportions and
common SNP variations [12–15]. However, mounting evidence suggests that this fatty acid pool
may be more affected by recent fat consumption [16], potentially obscuring the role of genetic
variation in determining fatty acid composition [4,17].
Here we report a GWAS exploring relationships between the relative proportions of fourteen
saturated, mono- and polyunsaturated RBC fatty acids with over 2.5 million common (minor
allele frequency >1%) SNPs in the Framingham Heart Offspring Study.
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2. Materials and Methods
2.1 Sample
Our analysis focused on the Framingham Heart Study (FHS) Offspring sample, a population
based longitudinal study of families living in Framingham, Massachusetts. Detailed descriptions
of the sample are available [4,18–20]. The final sample for this study consisted of 2633
individuals for whom both fatty acid and genotype data were available. The 2633 is a subset of
2899 Offspring subjects attending Examination 8 (2005-2008); those excluded due to missing
genotype data had similar demographic and fatty acid profiles as those included in the study
(data not shown). Written informed consent was provided by all participants, and the
Institutional Review Board at the Boston University Medical Center approved the study protocol.
2.2 Fatty acid measurements
The fatty acid composition of RBC samples were analyzed by gas chromatography equipped
with a SP 2560 capillary column after direct transesterification for 10 minutes in boron
trifluoride/ methanol and hexane at 100 C as previously described. [4]. This technique generates
fatty acids primarily from RBC glycerophospholipids. All fatty acids with at least 0.5%
abundance were included for analysis (except trans oleic acid): arachidonic acid (AA), dihomogamma-linoleneic acid (DGLA), docosahexaenoic acid (DHA), docosapentaenoic acid-n3 (DPAn3), docosapentaenoic acid-n6 (DPA-n6), docosatetraenoic acid (DTA), eicosapentaenoic acid
(EPA), linoleic acid (LA), oleic acid (OA), palmitic acid (PA), and stearic acid (SA). Three fatty
acids below the 0.5% abundance level were also included: Palmitoleic acid (POA), because it is
a marker of de novo lipogenesis [21]; gamma-linolenic acid (GLA), because it is the initial
product of LA metabolism via delta-6 desaturase [22]; and alpha-linolenic acid (ALA), because
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as a dietary essential fatty acid like LA, its levels should be under less metabolic control than
fatty acids that are the products of metabolism. Means and SDs of all 14 FAs are provided in
Supplemental Table 1.
2.3 Genotype data
This analysis is based on approximately 2.5 million autosomal CEU (Centre d’Etude du
Polymorphisme Humain collection from Utah; Northern and Western European ancestry)
HapMap SNPs which were measured directly (approximately 550,000) or imputed
(approximately 2 million) as previously reported [18]. Briefly, direct genotypes were obtained
using the Affymetrix 500K and MIPS 50K chips, and were analyzed at the Affymetrix Core
Laboratory. SNPs with missing data rates more than 3%, Hardy Weinberg Equilibrium p-values
less than 1x10-6, more than 100 Mendelian errors or low minor allele frequency (less than 1%)
were eliminated from consideration. Measured SNPs, along with HapMap (release 22, build 36,
CEU reference panel) [23] was used to impute the remaining 2 million SNPs using MaCH [24].
Quality control procedures were similar for both imputed and directly measured SNPs, with the
addition of standard imputation quality metrics for imputed SNPs (see [18] for details).
2.4 Statistical analysis
For each of the 14 fatty acids considered here, a linear mixed model was fit for each of the 2.5
million SNPs which passed the initial quality control criteria. Each regression model predicted
log10 -transformed fatty acid level by SNP genotype (number of minor alleles), adjusting for age,
sex and a random covariance component summarizing the family-structure present in the
Framingham data set (i.e. matrix of kinship coefficients). We reported partial r 2 values in the
text, which were percent change in the log of the relative fatty acid proportion explained by one
additional minor allele (i.e. additive genetic model). Linear mixed effects models using the
kinship matrix were run using R (lmekin function) for all analyses [25]. SNPs were considered
genome-wide significant if their p-value was less than 1x10-8. For each fatty acid, the distribution
of p-values was evaluated using a Q-Q plot, and the genomic control lambda value (GC) was


6

estimated. GC values ranged between 0.996 and 1.067 for the 8 fatty acids with at least one SNP
reaching genome-wide significance (p<1x10-8), showing little evidence for over-inflation of test
statistics [26]. A final model for each fatty acid was also computed which adjusted for age, sex
and kinship, as well as all significant SNPs, after eliminating SNPs showing strong pairwise
correlations (Pearson correlation above 0.7 between genotypes) with other SNPs in the model.

3. Results
The clinical characteristics for the FHS Offspring participants and their fatty acid levels have
been previously reported [4]; briefly they had a mean (SD) age of 66 (9) years, 54% were
female, 9% smoked, and nearly half were treated for hypertension (49%) and high cholesterol
(43%). They also had the following comorbidities: diabetes (14%), coronary heart disease
(11%), and congestive heart failure (3%).
In all, 470 linear mixed models of SNP-fatty acid combinations reached a genome-wide
significant p-value of less than 1x10-8 (Supplemental Table 2). Since some SNPs were related to
multiple fatty acids, there were a total of 191 different (i.e., uniquely associated) SNPs reaching
genome-wide significance for at least one fatty acid (see Supplemental Table 3). In general,
when multiple fatty acids were associated with the same SNP, the fatty acids were correlated
(details not shown), in part because they are often in the same metabolic pathway. Six of the
fatty acids in our analysis had no SNPs reach the genome-wide significance level (DHA, DPAn6, EPA, PA, POA and SA all1x10-8 <p-value<1x10-6), but eight of the fatty acids contained at
least one genome-wide significant SNP (see Supplemental Figures 1a-1h for Manhattan plots of
these eight fatty acids).
As expected, many of the 191 uniquely associated SNPs occur in close proximity to each other
[i.e., within a 1 mega-base (MB) region], and so we summarized the 191 unique associations by
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focusing on five distinct 1MB or smaller regions which contained all 191 uniquely associated
SNPs. Table 1 provides an overview of the five associated regions, summarizing location
information, the number of significantly associated SNPs, references to prior literature about the
functionality of the region and a listing of the associated fatty acids.

3.1 Chromosome 1
The single significant SNP in chromosome 1 (rs3811444) is located in TRIM58 (tripartite motif
containing 58), a gene located in 1q44 from base pair (bp) 248,020,501 to 248,043,440. SNP
rs3811444 is a C (common allele) to T (rarer allele) polymorphism, with T alleles associated
with lower levels of OA (partial r 2 =1.6%).

3.2 Chromosome 3
Three SNPs in and nearby to the PCOLCE2 (alt: PCPE2; procollagen C-endopeptidase enhancer
2) gene were significantly associated with AA levels (rs2248811, rs6778966, rs2581624) with pvalues ranging from 8x10-9 to 1.2x10-10. All three significant SNPs have similar minor allele
frequencies (~0.20), and yielded similar explanatory power for AA (partial r 2 values of 1.3 to
1.6%). PCOLCE2 starts at bp 142,536,702 and ends at 142,608,045 on chromosome 3. One of
the three significant SNPs (rs2248811) is located within an intron in PCOLCE2 (at 142,606,942),
with the other two SNPs located downstream (rs6778966 at 142,610,610; rs2581624 at
142,633,869). Little prior GWAS evidence exists involving SNPs in PCOLCE2. Figure 1 depicts
the regional association of AA on chromosome 3 near PCOLCE2, showing that three significant
SNPs are highly correlated. Table 2 shows that rs2581624 explained 1.6% of the change in AA.

3.3 Chromosome 6
Thirteen SNPs within a 46kb region of chromosome 6 were significantly related to DPA-n3
levels. This region contains two genes: SYCP2L (synaptonemal complex protein 2-like) and
ELOVL2 (ELOVL fatty acid elongase 2), which are located from 10,887,064 to 10,974,542 and
10,980,992 to 11,044,624, respectively. Seven of the significant SNPs were contained within
SYCP2L, five within ELOVL2 and one in the intergenic space between the two genes. All
significantly associated SNPs in this region had similar explanatory power (partial r 2 values
between 1.2 and 1.3%). Figure 2 illustrates that the genome-wide significant SNPs in the
ELOVL2-SYCP2L region are in linkage disequilibrium.
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3.4 Chromosome 11
The majority of 141 associated SNPs on chromosome 11 were contained within a 488kb region
of chromosome 11. This region contains nine distinct genes, with many of the genes (FADS2,

FADS1, FEN1, C11ORF9 and C11ORF10) showing associations with approximately half of the
fatty acids in our analysis. The remaining genes (BEST1, RAB3IL1, FADS3 and DAGLA) show
associations with between one and three fatty acids (see Table 2 for details). Full results are
provided in Supplemental Table 3 which provides p-values, minor allele frequencies and effect
size estimates for the SNPs in the region. We briefly describe three distinct subregions.
Our analysis identifies twenty-nine significant SNPs in the region in and upstream of DAGLA
(Diacylglycerol lipase, alpha; bp 61,119,554 to 61,273,052), showing associations with DGLA
levels for all SNPs, plus with AA for two of the twenty-nine SNPs. Associations with DGLA
levels were generally negative, though some SNPs showed positive association (partial r 2
between 1.7 and 3.4%; see Supplemental Table 3 for details).
The FADS genes (FADS1; FADS2; FADS3; fatty acid desaturase), along with nearby ORFs
(C11ORF9, FEN1 and C11ORF10) contain or are nearby to 86 significant SNPs, with most
SNPs associated with multiple FA, and widely varied direction and magnitude of effect (see
Supplemental Table 3 for details). Figure 3 shows the high correlation between associated SNPs
throughout the FADS region. Table 2 shows that SNPs in this region accounted for as much as
42% of the variability in DGLA levels.
Remaining SNPs near or contained in RAB3IL1 (RAB3A interacting protein; 13 SNPs) and
within or downstream of BEST 1 (Bestrophin 1) were mainly positively associated with DGLA
levels, with a handful of SNPs also related AA and LA levels (see Supplemental Table 3 for
details).
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3.5 Chromosome 12
All 33 significant SNPs on chromosome 12 are within a single 112 kb region which contains
multiple genes (PTPN6, PHB2, MBOAT5 (alt. LPCAT3) and C1S). These SNPs all show
association with OA and LA. Rare alleles were generally associated with lower OA levels and
higher LA levels, corresponding to the negative association between these two fatty acids in the
sample. Figure 4 illustrates the regional association for OA, showing strong correlation between
the genotypes of significant SNPs in this region (a similar effect is observed for significant LA
SNPs in this region). SNPs in this region accounted for as much as 4-8% of variation in LA and
OA levels (see Table 2).

3.6 Multivariable models
Table 3 illustrates the overall variation explained (model r 2 ) for each of the eight fatty acids
with at least one genome-wide significant SNP. In particular, a separate model predicting the
log-transformed fatty acid relative proportion for each of the eight fatty acids was predicted by
age and sex, and then all significant SNPs for the fatty acid were added to the model. In cases
where SNPs showed strong association with each other (Pearson correlation between genotypes
greater than 0.7), only one individual SNP from that group was added to the model. The model
predicting DGLA had the largest overall variability explained (53.5%), and only 0.1% of this
estimate was associated with age and sex. Models predicting AA, LA and OA explained 13.7%,
10.5% and 8.3% of the variation in the relative proportions of these fatty acids, respectively, with
all three models showing large improvements over models containing only age and sex (13.6%,
8.9% and 7.8% improvement, respectively). Models for ALA and DTA explained similar
amounts of overall variation (8.9% and 9.9%), but were driven largely by age and sex and not
SNP genotypic variation (1% and 1.6% improvement with SNP genotypes). Finally, models for
GLA and DPA-n3 explained less variation overall (6.1% and 6.4%), with approximately twothirds of the variation explained by age and sex (1.5% and 2.6% improvement with SNP
genotypes).
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4. Discussion and Conclusions
This report presents the results of the largest genome-wide association study of RBC fatty acid
composition to date. In our exploration of potential associations between 14 fatty acids and 2.5
million SNPs, we identified five distinct regions yielding associations reaching genome-wide
significance. Of these, two of the regions replicated prior results from genome-wide association
studies GWAS of serum fatty acid levels (Chromosome 6 (ELOVL2); Chromosome 11 (FADS
genes)), two were novel (Chromosome 3 (PCOLCE2) and Chromosome 12 (LPCAT3)) and one
identified a SNP on Chromosome 1 (TRIM58) with prior evidence of association to platelet and
RBC counts. We briefly discuss each of these distinct regions in light of their known biology and
prior GWAS evidence.

4.1 TRIM58
TRIM58 contains only a single significant SNP-fatty acid association. However, this SNP was
recently identified as significantly related to platelet [27] and RBC counts [28] in European
populations. The TRIM58 gene has also been associated with mean corpuscular volume in a
Japanese sample [29]. Despite prior association evidence with related phenotypes, its function
has no clear relationship with fatty acid metabolism. In addition, previous studies with fish oils
have not shown effects on platelet counts [30] (except with supraphysiological intakes [31]), but
do affect platelet function [e.g., aggregation [32,33], thrombin generation [34], activation].

4.2 PCOLCE2
To date fatty acid GWAS have not uncovered associations with SNPs in PCOLCE2. PCOLCE2
encodes the protein PCPE2 [35] which regulates apoA-I maturation [36], modulating apoA-I
levels [37]. ApoA-I is the major structural component of high density lipoproteins (HDL). While
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its role in reverse cholesterol transport is well known, HDL also transports a large portion of
plasma phospholipids, of which arachidonic acid (AA) is a major component. This provides a
plausible biological mechanism whereby SNPs could impart less effective maturation of apoA-I,
which could result in lower plasma HDL levels. Since HDL particles transport about 40% of the
plasma phospholipids, and since RBC membrane phospholipids exchange with lipoprotein
phospholipids (which carry AA), it is conceivable that SNPs in PCOLCE2 could impact RBC
membrane AA composition [38]. HDL levels themselves are strongly and repeatedly related to
cardiovascular disease outcomes [39,40] and this observation could reveal underlying
mechanisms, though recent evidence suggests all genetically-determined differences in HDL
levels are not consistently associated with differences in cardiovascular disease risk and, further,
that using HDL cholesterol as a target for therapy (i.e., intervening to raise low levels) is
ineffective at reducing risk for cardiovascular disease risk [41].

4.3 ELOVL2
Previous studies have identified SNPs in both ELOVL2 and the nearby gene SYCP2L as being
significantly related to fatty acid proportions in plasma phospholipids. In particular, Lemaitre et
al. [12] identified 2 SNPs in SYCP2L (rs6918936 with EPA levels and rs4713103 with DPA and
DHA levels). Both SNPs were identified as significant in our analysis, though only showing
significant association with DPA; DHA only attained sub-threshold significance (both with
p=2x10-6), and EPA even less (p>0.001) (details not shown). Additional SNPs within ELOVL2
have also been associated with plasma phospholipid fatty acid patterns, metabolite levels and
other metabolic traits [12,13,42,43]. Many of these SNPs are replicated in our analysis (details
not shown).
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ELOVL2 on chromosome 5 encodes a long chain fatty acid elongase. The elongase is one of
seven ELOVL-family proteins that act primarily on polyunsaturated fatty acids [44] and ELOVL2
is critical in the elongation of DPA n-3 to DHA [45] (see also Supplemental Figure 2). The
strong direct associations between DPA n-3 levels and SNPs in this gene provide further
evidence of this relationship. In the transformation of DPA-n3 to DHA, elongation to
tetracosapentaenoic acid (TPA; more commonly 24:5n3) by ELOVL2 is a key step, and SNPs
contributing to reduced efficiency in this process would be expected to produce more DPAn3,
less TPA, and less DHA as the end product. On the other hand, a functional mutation in ELOVL2
could also slow the synthesis of DPA n-3 from EPA. Although it is difficult to predict how these
two counterbalancing processes might affect DPA n-3 membrane content, our finding of a direct
relation between DPA n-3 and SNPs in ELOVL2 suggest, as have Gregory et al.[45], that
conversion to TPA may be the more rate-limiting step. We did not measure TPA, but it is worth
noting that while DHA did not achieve our threshold of significance, it was negatively associated
with the presence of many SNPs (1x10-5<p<5x10-7; details not shown). This evidence combined
with evidence from previous GWAS studies suggests that genetic variability may influence the
levels of long-chain polyunsaturated omega-3 fatty acids.

4.4 FADS
Our analysis identified many strong association signals on chromosome 11, all in or near the

FADS gene region which is well-documented to be associated with fatty acid proportions
[12,13]. The FADS genes (FADS1, FADS2 and FADS3) are fatty acid desaturase genes. The
proteins encoded by these genes are key enzymes involved in the the desaturation of n-3 and n-6
polyunsaturated fatty acids as follows: FADS1 desaturates at the delta-5 position [e.g., the
conversion of DGLA (20:3n6) to AA (20:4n6)] and FADS2 desaturates at the delta-6 position
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[e.g., the conversion of LA (18:2n6) to GLA (18:3n6)] [22,46]. FADS3 has non-specific, or
currently ill-defined desaturation activity (see also Supplemental Figure 2). Recent work has
identified two major haplotypes spanning FADS1 and FADS2. Our analyses support the
presence of these haplotypes in this sample, as well as the finding that the more common
haplotype is associated with increased efficiency of long-chain fatty acid synthesis [47].
Furthermore, these genes have been shown to be associated with a number of phenotypes in SNP
association studies, including certain plasma fatty acids [48,49], plasma lipoproteins [48,50], and
response to lipid therapy [51] as well as DNA methylation levels [52].
A nearby gene in which SNP associations were found (DAGLA) encodes diacylglycerol lipases

alpha. Two of the SNPs (rs1692120 (upstream) and rs198426 (within DAGLA)) found to be
significantly associated in our analysis have been shown in prior research to have significant
associations with DPA and ALA [12]. The lipase is a key enzyme in endocannabinoid synthesis
pathways [53] and has been previously identified as associated with plasma phospholipid n-3
fatty acids in the CHARGE consortium [12]. Endocannabinoids modify risk-related patterns
including having an effect on eating behavior. An association of diacylglycerol lipase SNPs with
the RBC membrane fatty acid composition is not necessarily intuitive, nor is it immediately
apparent why association are with increasing DGLA levels. It is also not apparent that the
association is because of endogenous RBC-DAGLA activity [54] or is a secondary consequence
of its activity in other tissues.

4.5 LPCAT3 (alt. MBOAT5)
Little to no evidence exists in the GWAS literature connecting this region of chromosome 12
with fatty acid and other phenotypes. LPCAT3 encodes lysophosphatidylcholine acyltransferase
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3, yielding a protein which mediates the transfer of fatty acids between glycerol-lipids. LPCAT3
favors the transfer of saturated, as opposed to unsaturated, fatty acids [55]. While other LPAT
genes have been identified in GWAS studies on lipid endpoints or, shown to be associated with
cardiovascular risk [48,56], LPCAT3 is a novel observation with SNPs explaining a modest
amount of variation in LA and OA. The sn2 position of phospholipids primarily carries
polyunsaturated fatty acids, and limitation of LPCAT3 activity increases the abundance of
polyunsaturated fatty acids, such as linoleic acid, over monounsaturated fatty acids such as oleic
acid as observed here. Given the general interest in altering the relative abundances of these two
fatty acid classes this association could provide valuable insight to underlying biology.
The only published reports correlating RBC fatty acid composition to endpoints in the
Framingham Offspring Cohort focused on the long-chain omega-3 fatty acids EPA and DHA or

trans fatty acids [4,7]. It is important to note that none of the SNP – fatty acid relations observed
in this current analysis found significant associations for any of these fatty acids. This is perhaps
because RBC levels of these fatty acids are more strongly determined by variations in dietary
intake than are any other fatty acids [57,58]. However, other explanations are also possible (see
following paragraph for some details). We previously reported that “heritability” explained much
of the variability in RBC EPA+DHA (the Omega-3 Index) in this cohort [4]. When estimates of
EPA+DHA intake (from food and supplements) were added to the model, the proportion of
variability assigned to heritability diminished from 50% to 32%, suggesting that commonalities
in eating patterns among families accounted for a large portion of heritability. In the present
analysis, dietary fatty acid intake was not taken into account (since fatty acid intake data were
not available for 1/4 of the cohort), and thus our ability to detect genetic influences was likely
diminished due to unaccounted effects of diet on RBC fatty acid patterns. Other efforts have
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suggested 40-70% of variation in fatty acids is accounted for by genetic variation [9]. However,
multiple types of genetic information from very large cohorts may be needed to reveal genetic
vs. non-genetic influences in phenotypes [59].

4.6 Limitations
While this analysis has yielded a mix of biologically plausible novel genetic loci, as well as
replicating prior genome-wide associations, there are a few limitations worth noting. The first
was the lack of dietary data (especially relevant for EPA and DHA) described above, with the
related issue that proportions of multiple RBC fatty acids can be highly inter-correlated [4].
Further work is necessary to develop fatty acid-specific models that leverage dietary covariates,
that explicitly model the complex correlation structure between fatty acids, and that consider
ratios of fatty acids as opposed to single fatty acids. Second, our analysis only considers common
variants. Exome sequencing of the Framingham Offspring cohort is ongoing, and future analyses
should consider the potential role of rare genetic variation in explaining fatty acid levels. Third,
the family structure of the Framingham data meant that the effective sample size for our analysis
was lower than the actual sample size of 2,633, limiting power to identify associated SNPs.
Fourth, as is the case with any genome-wide association study, use of conservative significance
levels, as we have done here, provides protection against false positives, but can lead to reduced
ability (low power) to identify additional phenotype-genotype associations. Alternative methods
(e.g., candidate gene/pathway analyses that build more biologically-informed statistical models),
combining this sample with others, or gathering additional larger samples will be needed to
further characterize potential gene-fatty acid relationships. These further analyses should also
consider the potential role that rare (MAF<1%) genetic variation may play in fatty acid
metabolism. Finally, replication of the novel loci identified in this paper should be sought after
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in independent samples, along with consideration of impact of causal loci on gene expression
and associations with DNA methylation.

4.7 Conclusions
In seeking SNP relations for fourteen red blood fatty acid levels, we identified three novel loci,
and replicated two others. Further work is needed to fine map the new regions of genetic interest
(PCOLCE2, LPCAT3 and TRIM58) in independent samples, and analyze data using more
biologically-informed models to potentially establish causal relationships between genetic
variation and fatty acid metabolism.
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Figures
Figure 1. Regional association plot of PCOLCE2 locus with Arachidonic Acid (AA) levels.
Correlations between the target SNP (rs2581624; the SNP with the lowest p-value (1.19x10-10))
and nearby SNPs (within a 500kb) region are highlighted. Genotypes at rs2581624 are highly
correlated with both rs2248811 (intergenic) and rs6778966 (intra-genic), both of which also
reach genome-wide significance (-logP>8). r 2 values were based on the HapMap CEU
population.
Figure 2. Regional association plot of ELOVL2-SYCP2L locus with Docosapentaenoic Acid-n3
(DPA-n3) levels. Correlations between the target SNP (rs8523; the SNP with the lowest p-value
(4x10-9)) and nearby SNPs (within a 500kb) region are highlighted, showing strong correlations
between genome-wide significant SNPs in this region. r 2 values were based on the HapMap
CEU population.
Figure 3. Regional association plot of FADS locus with Dihomo-gamma-linoleic acid (DGLA)
levels. Correlations between the target SNP (rs174601) and nearby SNPs (within a 500kb) region
are highlighted, showing strong correlations between genome-wide significant SNPs in this
region between C11orf9 and FADS3, with less association with SNPs in DAGLA and BEST1. r 2
values were based on the HapMap CEU population.
Figure 4. Regional association plot of LPCAT3 locus with Oleic Acid (OA) levels. Correlations
between the target SNP (rs2110073) and nearby SNPs (within a 500kb) region are highlighted,
showing strong correlations between genome-wide significant SNPs in this region. r 2 values
were based on the HapMap CEU population.
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Table 1. Summary of genome-wide association results
Location
(kb)

# sig.
SNPs1

Genes containing
SNPs

Prior GWAS
evidence?2

Plausible biological
mechanism to alter fatty
acid level

Smallest p-value (rs#;

1

Size
of
regio
n
(kb)
1

246106

1

TRIM58

Unknown

3

27

144090144117

3

PCOLCE2

Yes
[27–29]
No

6

46

1111411068

13

SYCP2L
ELVOL2

Yes
[12,13,42,43]

Elongation of n3-DPA to
DHA

11

488

6112061608

141

DAGLA
C11orf10
C11orf9
FEN1
FADS1
FADS2
FADS3
RAB3IL1
BEST1

Yes [12,13]3

5x10-11 (rs3811444;
0.016: OA)
1x10-10
(rs6778966
0.016: AA)
1x10-10
(rs3798707;
0.012: DPA-n3)
3x10-305
(rs174601;
OA: 0.017,
LA: 0.058,
ALA: 0.012,
DGLA: 0.35,
AA: 0.122,
DPA-n3: 0.024)

PTPN6
PHB2
LPCAT3 (alt.
MBOAT5)
C1S

No

Chr

12

112

6940-7051

33

Regulator/Modulator of
apoA-I

Desaturation of fatty acids

Mediates the transfer of
fatty acids between
glycerol-lipids

1

All 191 SNP IDs are provided in Supplemental Table 3

2

Based on search at http://www.genome.gov/gwastudies/

3

Among many others



r 2 : Fatty Acid)

3x10-49
(rs2110073;
OA: 0.079,
LA: 0.039)
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Table 2. Variation in fatty acids explained by significant SNPs
Strongest single SNP association1
Chr

Fatty

Gene

rs#

Acid

Minor
allele

Partial

r

Standardized beta

2

1

OA

TRIM58

rs3811444

T

0.016

-0.13

3

AA

PCOLCE2

rs2581624

C

0.016

-0.13

6

DPA-n3

ELOVL2

rs8523

A

0.013

0.11

11

DGLA

FADS1

rs174548

G

0.418

0.65

C11ORF9

rs509360

A

0.200

-0.45

LA

LPCAT3

rs12580543

C

0.044

0.21

OA

PHB2

rs2110073

T

0.079

-0.28

12

2

The SNP-FA with the largest partial r , i.e. proportion of variability in the fatty acid explained by changes in the SNP genotypes adjusted for
age and gender, in the region. Estimated from the age and sex adjusted model. In cases where there were SNPs with opposite direction effects the
strongest positively and the strongest negatively associated SNPs are reported.
1
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Table 3. Total variation in fatty acids explained by significant SNPs (model r 2 )

r2
Fatty Acid

of Multivariable models

Age+Sex Only

Age+Sex+

Additional variance explained by SNP

All Significant
SNPs1

1

AA

0.1%

13.7%

13.6%

ALA

7.9%

8.9%

1.0%

DGLA

0.1%

53.5%

53.4%

DTA

8.3%

9.9%

1.6%

GLA

4.4%

6.1%

1.7%

LA

1.6%

10.5%

8.9%

OA

0.5%

8.3%

7.8%

DPA-n3

3.8%

6.4%

2.6%

After eliminating highly correlated SNPs, so that genotypes between all pairs of genome-wide significant SNPs in the model have pairwise
Pearson correlation coefficients less than 0.7
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Highlights
-

We analyzed over 2.5 million SNPs for association with 14 RBC fatty acids, one of the
largest GWAS studies of RBC fatty acids to date



-

We identified novel associations with PCOLCE2 and LPCAT3

-

We replicated previous strong associations with FADS and ELOVL
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Figure 3
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